medigraphic.com

2016, Number 4

<< Back Next >>

Rev Hematol Mex 2016; 17 (4)

Primary immune thrombocytopenia. Hematologist consensus 2016. ISSSTE

Alvarado-Ibarra M, Aguilar-Andrade C, Álvarez-Vera JL, Amador-Pérez AO, Anaya-Cuéllar I, Añorve-Hernández E, Báez-Islas PE, Bates-Martín RA, Cervantes-Sánchez I, Choque-Condori DI, Cortés-Sánchez E, García- Camacho AS, García-Fernández L, Gómez-Rosas P, Grimaldo-Gómez FA, Guillén-Conde ON, Hernández-Ruiz E, Herrera-Olivares W, Leyto-Cruz F, Loera-Fragoso SJ, Martínez-Ramírez MA, Merino-Pasaye LE, Miranda- Madrazo MR, Mojica-Balceras L, Mujica-Martínez A, Paredes-Lozano EP, Pérez-Zúñiga JM, Pichardo-Cepín Y, Ramos-León EM, Reséndiz-Olea R, Rojas-Castillejos F, Ron-Guerrero CS, Saavedra-Hernández MA, Salazar- Ramírez O, Silva-Vera K, Vilchis-González P

Language: Spanish
References: 64
Page: 268-286
PDF size: 682.74 Kb.


ABSTRACT

Often, the recommendations of foreign guidelines may be applied in Mexico, both by lack of resources such as cultural differences of doctors and patients, entrenched customs, different access to information, different conditions of food and housing, among other. Sometimes modifications can be made to the recommended schemes that reduce costs without losing therapeutic effectiveness. Since the emergence of evidence-based medicine in the 1980, the clinical practice guidelines have become increasingly important tools to set the standard for quality and patient care. The growing influence of the guidelines has attracted scrutiny progressive development of these methods, since they must disclose the advantages and limitations based on the available scientific evidence. Over the last two classification systems decades force recommendations they have evolved, becoming more sophisticated.


REFERENCES

  1. Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013;90:494-500. doi:10.1111/ejh.12102.

  2. Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 2005;56:425- 442. doi:10.1146/annurev.med.56.082103.104644.

  3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-2393. doi:10.1182/blood-2008-07-162503.

  4. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011;118:28-36. doi:10.1182/ blood-2010-10-313908.

  5. Keating GM. Romiplostim: a review of its use in immune thrombocytopenia. Drugs 2012;72:415-435. doi:10.2165/11208260-000000000-00000.

  6. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83:83-89. doi:10.1111/j.1600- 0609.2009.01247.x.

  7. Lo E, Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 2014;13:577- 583. doi:10.1016/j.autrev.2014.01.026.

  8. Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015;41:395-404. doi:10.1055/s-0034-1544001.

  9. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009;145:235-244. doi:10.1111/j.1365-2141.2009.07615.x.

  10. Sanz MA, Vicente García V, Fernández A, Sociedad Española de Hematología y Hemoterapia, Sociedad Española de Hematología y Oncología Pediátricas y col. Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia. Med Clin (Barc) 2012;138:261.

  11. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984;64:1179-1183.

  12. Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol Suppl 2009;82:8-12. doi:10.1111/j.1600-0609.2008.01207.x.

  13. George JN, Vesely SK, Woolf SH. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. Am J Med Qual 2014;29:53-60. doi:10.1177/1062860613481618.

  14. Lopez MA, Alvarado M, Medina L. Trombocitopenia inmune primaria diagnostico y tratamiento. 2015 ed. Española EA, 2015.

  15. Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol 2011;152(1):52-60. doi:10.1111/j.1365- 2141.2010.08412.x.

  16. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008;30:5- 11. doi:10.1016/j.jaut.2007.11.009.

  17. Ron-Guerrero CS. Diferencias clínicas de la trombocitopenia inmunitaria entre los niños y los adultos: posible explicación patogénica. Rev Hematol Mex 2014;15:142-147.

  18. López MA, Medina L, Alvarado M, Álvarez JL. Tratamiento de la púrpura trombocitopénica inmunitaria. Experiencia en un solo hospital. Medicina Interna de México 2015;31:3-12.

  19. Neunert C, Arnold DM. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply. J Thromb Haemost 2015;13:1522- 1523. doi:10.1111/jth.13019.

  20. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186. doi:10.1182/blood-2009-06-225565.

  21. Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta analysis. Eur J Haematol 2016;97:321-330. doi:10.1111/ ejh.12777.

  22. Fierro A. Púrpuras. Trombocitopenia inmune primaria. Pediatr integral 2012;XVI:399-412.

  23. Arnold DM, Stasi R. Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008:31-32. doi:10.1182/asheducation-2008.1.31.

  24. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231-1240. doi:10.1182/ blood-2008-07-167155.

  25. Liebman HA. Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008:212-218. doi:10.1182/asheducation-2008.1.212.

  26. Nakajima H, Takagi H, Yamazaki Y, et al. Immune thrombocytopenic purpura in patients with hepatitis C virus infection. Hepatogastroenterology 2005;52:1197-1200.

  27. Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther 2015;32:875-887. doi:10.1007/s12325-015-0251-z.

  28. Parrondo J. Evaluación económica del tratamiento de la trombocitopenia inmune primaria crónica refractaria con agonistas del receptor de la trombopoyetina. Farm Hosp 2013;37:1-10. doi:10.7399/FH.2013.37.3.526.

  29. Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs 2011;71:1333-1353. doi:10.2165/11207390-000000000-00000.

  30. Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol 2013;91:423-436. doi:10.1111/ ejh.12181.

  31. Sanz M. Long-term management of chronic immune thrombocytopenic purpura in adults. Int J Gen Med 2010;3:305- 307. doi:10.2147/IJGM.S4722.

  32. Lozano ML, Revilla N, González-López TJ, et al. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol 2016;95:1089-1098. doi:10.1007/s00277- 016-2665-3.

  33. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377:393-402. doi:10.1016/S0140-6736(10)60959-2.

  34. Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr 2015;3:163-165. doi:10.3389/fped.2015.00070.

  35. Valencia LO. EyR_SSA_301_10. 2015:1-54.

  36. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-969. doi:10.1182/blood-2011-12-309153.

  37. De Mattia D, Del Vecchio GC, Russo G, et al. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol 2010;123:96- 109. doi:10.1159/000268855.

  38. Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, et al. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. J Clin Pharm Ther 2014;39:376-382. doi:10.1111/jcpt.12156.

  39. Zhang WG, Ji L, Cao XM, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 2005;26:598-602. doi:10.1111/j.1745-7254.2005.00088.x.

  40. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Current Opinion in Hematology 2012;19:392-398. doi:10.1097/MOH.0b013e328356e909.

  41. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545. doi:10.1182/ blood-2012-04-425512.

  42. Vlachaki E, Papageorgiou V, Klonizakis F, et al. Total remission of severe immune thrombocytopenia after short term treatment with romiplostim. Hematol Rep 2011;3:1-2. doi:10.4081/hr.2011.e20.

  43. Carpenedo M, Cantoni S, Coccini V, Fedele M, et al. Feasibility of romiplostim discontinuation in adult thrombopoietin- receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep 2015;7:1-4. doi:10.4081/hr.2015.5673.

  44. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015;90:40-43. doi:10.1002/ ajh.23900.

  45. McCrae KR. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program 2010;2010:397-402. doi:10.1182/asheducation-2010.1.397.

  46. Quick Reference. June 2016:1-4.

  47. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207. doi:10.1182/blood-2010-08-302984.

  48. Verdugo LP, Kabalan BP, Silva CR y col. Guías clínicas para el manejo del paciente pediátrico con trombocitopenia inmune primaria (PTI). Rev Chil Pediatr 2011;82:351-357. doi:10.4067/S0370-41062011000400010.

  49. Terrell DR, Beebe LA, Vesely SK, Neas BR, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010;85:174-180. doi:10.1002/ajh.21616.

  50. Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011;117:5723-5732. doi:10.1182/blood-2010-11-321398.

  51. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008. doi:10.1056/ NEJMra010501.

  52. Perricone C, Ceccarelli F, Nesher G, et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res 2014;60:226-235. doi:10.1007/s12026-014-8597-x.

  53. Dubansky AS, Boyett JM, Falletta J, et al. Isolated thrombocytopenia in children with acute lymphoblastic leukemia: a rare event in a Pediatric Oncology Group Study. Pediatrics 1989;84:1068-1071.

  54. Despotovic JM, Lambert MP, Herman JH, et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion 2012;52:1126-1136- quiz1125. doi:10.1111/j.1537-2995.2011.03384.x.

  55. Despotovic JM, Neunert CE. Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia? Hematology Am Soc Hematol Educ Program 2013;2013:283-285. doi:10.1182/asheducation- 2013.1.283.

  56. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-5995. doi:10.1182/blood-2011-11-393975.

  57. Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One 2012;7:36698. doi:10.1371/journal.pone.0036698.

  58. Schiavotto C, Castaman G, Rodeghiero F. Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and/or splenectomy with immunosuppressive therapy and danazol. Haematologica 1993;78:29-34.

  59. Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP. Low-dose cyclosporin a therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:77-79.

  60. Gesundheit B, Cividalli G, Freeman A, Yatziv S, et al. Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children. Eur J Haematol 2001;66:347-351.

  61. Generali JA, Cada DJ. Dexamethasone: idiopathic thrombocytopenic purpura in children and adolescents. Hosp Pharm 2013;48:108-110. doi:10.1310/hpj4802-108.test.

  62. Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura. Am J Dis Child 1988;142:1317-1319.

  63. Schiavotto C, Ruggeri M, Rodeghiero F. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol 1995;70:89-90.

  64. Chaturvedi S, McCrae KR. Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet 2016;388:4-6. doi:10.1016/S0140-6736(16)00589-4.




2020     |     www.medigraphic.com